


Pharmaceuticals & Biotechnology | Small Cap
Wockhardt Ltd, a company in the Healthcare Services industry, showcases a mixed financial performance. The company demonstrates strong solvency, driven by healthy debt and equity management. Growth prospects are promising, particularly in revenue and operating profit. However, certain areas raise concern. The company's liquidity position appears weak, suggesting potential challenges in meeting short-term obligations. Efficiency in utilizing assets is also a concern. Profitability metrics are inconsistent, with strong gross and operating margins offset by low returns on equity and assets. Overall, Wockhardt shows potential for growth and stability, but needs to address its liquidity and efficiency challenges to achieve sustained financial health.
Wockhardt Ltd, a company in the Healthcare Services industry, showcases a mixed financial performance. The company demonstrates strong solvency, driven by healthy debt and equity management. Growth prospects are promising, particularly in revenue and operating profit. However, certain areas raise concern. The company's liquidity position appears weak, suggesting potential challenges in meeting short-term obligations. Efficiency in utilizing assets is also a concern. Profitability metrics are inconsistent, with strong gross and operating margins offset by low returns on equity and assets. Overall, Wockhardt shows potential for growth and stability, but needs to address its liquidity and efficiency challenges to achieve sustained financial health.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
101.23
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
150.65
P/B RATIO
6.50
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
8.34
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
0.00
EV/EBITDA RATIO
43.51
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1975 as on Aug 6, 2026.
The company demonstrates strong growth in revenue and operating profit. The company has experienced decline in earnings per share, and net income growth rate is also low. However, the company has been able to grow its assets. The company's growth prospects appear to be promising, particularly in revenue and operating profit. Overall, the company's growth ratio indicates a mixed performance.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 19.28 | -17.93 | 5.55 | 7.65 | 11.99 |
| Operating Profit Growth Rate | -573.02 | -66.11 | -9.9 | 331.87 | 65.9 |
| Earnings Per Share (EPS) Growth | -135.56 | 129.04 | -22.22 | -90.42 | -553.63 |
| Asset Growth Rate | 6.08 | -6.87 | -0.48 | 6.38 | 6.36 |
| Net Income Growth Rate | -140.49 | 122.58 | -23.99 | -87.92 | -449.12 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 2 | Gland Pharma Ltd | 7.91 | 41.83 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 3 | Neuland Laboratories Ltd | 7.84 | 75.93 | Highly Overvalued | 574.00 | 283.01 | 364.00 |
| 4 | Granules India Ltd | 7.73 | 34.93 | Highly Overvalued | 1185.00 | 16.17 | 595.00 |
| 5 | Ajanta Pharma Ltd | 7.72 | 41.06 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 6 | Alembic Pharmaceuticals Ltd | 7.60 | 24.31 | Undervalued | 1118.00 | 32.58 | 671.00 |
| 7 | Emcure Pharmaceuticals Ltd | 7.40 | 39.72 | Neutral | 1865.00 | 38.64 | 941.00 |
| 8 | Marksans Pharma Ltd | 7.24 | 29.16 | Neutral | 601.00 | 6.64 | 420.00 |
| 9 | Syngene International Ltd | 7.16 | 50.86 | Overvalued | 918.00 | 7.55 | 317.00 |
| 10 | ERIS Lifesciences Ltd | 7.15 | 30.92 | Neutral | 1120.00 | 17.61 | 648.00 |
| 11 | Piramal Pharma Ltd | 5.83 | -85.00 | Neutral | 922.00 | 5.26 | -326.00 |
| 12 | Jubilant Pharmova Ltd | 5.71 | 37.02 | Neutral | 1260.00 | 1.25 | 398.00 |
| 13 | Natco Pharma Ltd | 5.69 | 11.52 | Neutral | 1436.00 | 71.55 | 1418.00 |
| 14 | Strides Pharma Science Ltd | 5.55 | 16.53 | Undervalued | 925.00 | 19.92 | 575.00 |
| 15 | Jeena Sikho Lifecare Ltd | 5.52 | 33.85 | Neutral | 349.00 | 17.87 | 222.00 |
| 16 | Wockhardt Ltd | 5.07 | 150.65 | Neutral | 652.00 | 19.51 | 199.00 |
| 17 | Pfizer Ltd | 3.45 | 48.81 | Neutral | -82.00 | 157.92 | 300.00 |
| 18 | Procter & Gamble Health Ltd | 3.45 | 30.81 | Neutral | 457.00 | 196.94 | 327.00 |
| 19 | Sanofi India Ltd | 3.45 | 18.66 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤11th Jun 26
Q4 FY26 Earnings Conference Call
BULLISH SENTIMENT